C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
C4 Therapeutics (NASDAQ: CCCC) announced that company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
The fireside chat is scheduled for Wednesday, February 11, 2026 at 11:30 AM ET. A live webcast will be available on the company’s Investors website, with an archived replay accessible for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CCCC
In the Feb 4 session, CCCC declined 5.97%, reflecting a notable negative market reaction. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Inducement option grant | Neutral | +3.4% | Single-employee stock option inducement grant under Nasdaq Rule 5635(c)(4). |
| Jan 14 | Program milestones update | Positive | +0.9% | Outlined cemsidomide milestones, Phase 2/1b plans, and cash runway to 2028. |
| Nov 25 | Conference participation | Neutral | +0.8% | Announced fireside chat at 8th Annual Evercore Healthcare Conference. |
| Nov 06 | Q3 2025 earnings | Positive | +0.4% | Reported Q3 2025 financials, $125M equity raise, and positive cemsidomide data. |
| Oct 16 | Underwritten equity offering | Negative | +11.7% | $125M offering with shares, pre-funded and other warrants at set package prices. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CCCC news has generally seen small positive price reactions, with an underwritten offering on Oct 16, 2025 the only clear divergence, as shares rose 11.71% on potentially dilutive news.
Over the past few months, C4 Therapeutics has combined capital-raising with steady clinical and corporate updates. An underwritten offering in Oct 2025 raised $125 million, followed by Q3 2025 results with $11.2 million in revenue and detailed cemsidomide data. Strategic milestones through 2028 and an inducement option grant in Jan 2026 were also disclosed. Prior conference participation in Nov 2025 mirrors today’s Guggenheim summit appearance as part of an ongoing investor-relations cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY.
Fireside Chat Details:
Date: Wednesday, February 11, 2026
Time: 11:30 AM ET
A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 90 days following the event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
